Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions

Eduard Badarau, Zhuo Wang, Dan L. Rathbone, Andrea Costanzi, Thomas Thibault, Colin E. Murdoch, Said El Alaoui, Milda Bartkeviciute, Martin Griffin

Research output: Contribution to journalArticle

Abstract

Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition.

LanguageEnglish
Pages1347-1361
Number of pages15
JournalChemistry and Biology
Volume22
Issue number10
Early online date9 Oct 2015
DOIs
Publication statusPublished - 22 Oct 2015

Fingerprint

Endothelial cells
Fibronectins
Syndecan-4
Umbilical Cord
Peptidomimetics
Derivatives
Ionomycin
Endothelial Cells
Molecular dynamics
Nephrosclerosis
Intracellular Space
Collagen
Cells
Ligands
Extracellular Space
Molecular Dynamics Simulation
Human Activities
Cell Movement
Extracellular Matrix
Enzymes

Bibliographical note

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Cell Press papers are freely available starting 12 months after publication.

Supplementary Information: http://dx.doi.org/10.1016/j.chembiol.2015.08.013

Keywords

  • irreversible tissue transglutaminase inhibitors

Cite this

Badarau, Eduard ; Wang, Zhuo ; Rathbone, Dan L. ; Costanzi, Andrea ; Thibault, Thomas ; Murdoch, Colin E. ; El Alaoui, Said ; Bartkeviciute, Milda ; Griffin, Martin. / Development of potent and selective tissue transglutaminase inhibitors : their effect on TG2 function and application in pathological conditions. In: Chemistry and Biology. 2015 ; Vol. 22, No. 10. pp. 1347-1361.
@article{5e8ec2eb3ad4428fb12e526a590096f6,
title = "Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions",
abstract = "Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40{\%} reduction in collagen deposition.",
keywords = "irreversible tissue transglutaminase inhibitors",
author = "Eduard Badarau and Zhuo Wang and Rathbone, {Dan L.} and Andrea Costanzi and Thomas Thibault and Murdoch, {Colin E.} and {El Alaoui}, Said and Milda Bartkeviciute and Martin Griffin",
note = "{\circledC} 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Cell Press papers are freely available starting 12 months after publication. Supplementary Information: http://dx.doi.org/10.1016/j.chembiol.2015.08.013",
year = "2015",
month = "10",
day = "22",
doi = "10.1016/j.chembiol.2015.08.013",
language = "English",
volume = "22",
pages = "1347--1361",
journal = "Chemistry and Biology",
issn = "1074-5521",
publisher = "Elsevier",
number = "10",

}

Development of potent and selective tissue transglutaminase inhibitors : their effect on TG2 function and application in pathological conditions. / Badarau, Eduard; Wang, Zhuo; Rathbone, Dan L.; Costanzi, Andrea; Thibault, Thomas; Murdoch, Colin E.; El Alaoui, Said; Bartkeviciute, Milda; Griffin, Martin.

In: Chemistry and Biology, Vol. 22, No. 10, 22.10.2015, p. 1347-1361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of potent and selective tissue transglutaminase inhibitors

T2 - Chemistry and Biology

AU - Badarau, Eduard

AU - Wang, Zhuo

AU - Rathbone, Dan L.

AU - Costanzi, Andrea

AU - Thibault, Thomas

AU - Murdoch, Colin E.

AU - El Alaoui, Said

AU - Bartkeviciute, Milda

AU - Griffin, Martin

N1 - © 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Cell Press papers are freely available starting 12 months after publication. Supplementary Information: http://dx.doi.org/10.1016/j.chembiol.2015.08.013

PY - 2015/10/22

Y1 - 2015/10/22

N2 - Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition.

AB - Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition.

KW - irreversible tissue transglutaminase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84950275624&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2015.08.013

DO - 10.1016/j.chembiol.2015.08.013

M3 - Article

VL - 22

SP - 1347

EP - 1361

JO - Chemistry and Biology

JF - Chemistry and Biology

SN - 1074-5521

IS - 10

ER -